registHER: An observational cohort study of patients with HER2+metastatic breast cancer

被引：0
|
作者：
Yood, Marianne Ulcickas [1 ,2 ]
Kaufman, Peter A. [3 ,4 ]
Mayer, Musa [5 ]
Rugo, Hope [6 ]
Brufsky, Adam [7 ]
Tan-Chiu, Elizabeth [8 ]
Yardley, Denise [9 ]
Paik, Soonmyung [10 ]
Wang, Lisa [11 ]
Birkner, Merrill [11 ]
Brammer, Melissa [11 ]
Tripathy, Debu [12 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] EpiSource, Hamden, CT USA
[3] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[4] Norris Cotton Canc Ctr, Lebanon, NH USA
[5] AdvancedBC Org, New York, NY USA
[6] UCSF, Ctr Comprehens Canc, San Francisco, CA USA
[7] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA
[8] Florida Canc Care, Tamarac, FL USA
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Natl Surtal Breast & Bowel Project, Pittsburgh, PA USA
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
090
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [41] Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+Metastatic Breast Cancer: The DE-REAL Study
    Botticelli, Andrea
    Caputo, Roberta
    Scagnoli, Simone
    Pisegna, Simona
    De Laurentiis, Michelino
    Curigliano, Giuseppe
    Lambertini, Matteo
    Pantano, Francesco
    Palazzo, Antonella
    Paris, Ida
    Vernieri, Claudio
    Tedesco, Beatrice
    Giampaglia, Marianna
    Palleschi, Michela
    Ballatore, Zelmira
    Alesini, Daniele
    D'Auria, Giuliana
    Fabbri, Agnese
    Rossi, Luigi
    Verrazzo, Annarita
    Scafetta, Roberta
    Marinelli, Daniele
    Sposetti, Caterina
    Barberi, Vittoria
    Strigari, Lidia
    Marchetti, Paolo
    Santini, Daniele
    Fabi, Alessandra
    ONCOLOGIST, 2024, 29 (04): : 303 - 310
  • [42] registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer.
    Yardley, D. A.
    Kaufman, P. A.
    Mayer, M.
    Ulcickas, Yood M.
    Tan-Chiu, E.
    Brufsky, A. M.
    Rugo, H. S.
    Tripathy, D.
    Brammer, M. G.
    Paik, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S263 - S264
  • [43] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
    Park-Simon, T. -W
    Okines, A.
    Paplomata, E.
    Wahl, T.
    Wright, G.
    Sutherland, S.
    Jakobsen, E.
    Valdes-Albini, F.
    Chan, A.
    Clark, A. S.
    Conlin, A.
    Lustberg, M.
    Specht, J.
    Pluard, T.
    Zhu, X.
    Krop, I
    Gelmon, K.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 243 - 244
  • [44] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
    Okines, Alicia Frances Clare
    Paplomata, Elisavet
    Wahl, Tanya A.
    Wright, Gail Lynn Shaw
    Sutherland, Stephanie
    Jakobsen, Erik
    Valdes, Frances
    Chan, Arlene
    Clark, Amy Sanders
    Conlin, Alison Katherine
    Lustberg, Maryam B.
    Specht, Jennifer M.
    Pluard, Timothy J.
    Zhu, Xiaofu
    Krop, Ian E.
    Gelmon, Karen A.
    Slamon, Dennis J.
    Ramos, Jorge
    An, Grace
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Optimizing outcomes in patients (pts) with HER2+metastatic breast cancer (MBC) through continuous inhibition of HER2 activity: A single institution study
    Fedele, P.
    Orlando, L.
    Schiavone, P.
    Calvani, N.
    Marino, A.
    Nacci, A.
    Sponziello, F.
    Mazzoni, E.
    Rizzo, P.
    Cinieri, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Use and safety of trastuzumab emtansin in HER2+metastatic breast cancer in a tertiary hospital
    Chaguaceda Galisteo, C.
    Manzaneque Gordon, Alba
    Del Rio Torres, Hector Jose
    Baro, Natalia Creus
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 286 - 286
  • [47] Trastuzumab for HER2+metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival
    Rossi, Marta
    Carioli, Greta
    Bonifazi, Martina
    Zambelli, Alberto
    Franchi, Matteo
    Moja, Lorenzo
    Zambon, Antonella
    Corrao, Giovanni
    La Vecchia, Carlo
    Zocchetti, Carlo
    Negri, Eva
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 41 - 49
  • [48] Systemic treatment of HER2+metastatic breast cancer: Clinical conundrums and future perspectives
    De Boer, Richard
    Beith, Jane
    Chirgwin, Jacquie
    Chua, Sue
    Colosimo, Maree
    Francis, Prudence
    Green, Michael
    Pittman, Ken
    White, Michelle
    Wilcken, Nicholas
    Zdenkowski, Nicholas
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 15 - 25
  • [49] Treatment patterns and their impact on the outcome of patients with HR+/HER2+metastatic breast cancer in a large real-world cohort.
    Carausu, Marcela
    Carton, Matthieu
    Dieras, Veronique C.
    Petit, Thierry
    Lahaye, Severine Guiu
    Veyret, Corinne
    Goncalves, Anthony
    Augereau, Paule
    Ferrero, Jean-Marc
    Levy, Christelle
    Ung, Mony
    Desmoulins, Isabelle
    Debled, Marc
    Bachelot, Thomas
    Eymard, Jean-Christophe
    Pistilli, Barbara
    Frenel, Jean-Sebastien
    Chevrot, Michael
    Mailliez, Audrey
    Cabel, Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Experience and impact of alopecia in patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry.
    Mason, Ginny
    Mayer, Musa
    Swain, Sandra M.
    Kaufman, Peter
    Tripathy, Debu
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Yardley, Denise A.
    Brufsky, Adam
    Rugo, Hope S.
    Cobleigh, Melody A.
    Chu, Laura Kay
    Antao, Vincent P.
    Morris, Anne
    Yoo, Bongin
    Jahanzeb, Mohammad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
12345